David Alan Campbell - Jan 3, 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Executive Officer, Director
Signature
/s/ Maria Dobek, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 04:21 PM
Previous filing
Jun 10, 2021
Next filing
Jan 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +354K $0.00 354K Jan 3, 2022 Common Stock 354K $20.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period.